{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:04:03Z","timestamp":1792166643327,"version":"4.4.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s12325-014-0174-0","type":"journal-article","created":{"date-parts":[[2014,12,16]],"date-time":"2014-12-16T14:10:44Z","timestamp":1418739044000},"page":"1197-1212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Management of Bone Disease in Gaucher Disease Type 1: Clinical Practice"],"prefix":"10.1007","volume":"31","author":[{"given":"Gaetano","family":"Giuffrida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Domenica","family":"Cappellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Carubbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Di Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Iolascon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,17]]},"reference":[{"key":"174_CR1","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","volume":"372","author":"GA Grabowski","year":"2008","unstructured":"Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher\u2019s disease. Lancet. 2008;372:1263\u201371.","journal-title":"Lancet"},{"key":"174_CR2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249\u201354.","journal-title":"JAMA"},{"key":"174_CR3","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3324\/haematol.12379","volume":"93","author":"M Rocco Di","year":"2008","unstructured":"Di Rocco M, Giona F, Carubbi F, et al. A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease. Haematologica. 2008;93:1211\u20138.","journal-title":"Haematologica"},{"key":"174_CR4","first-page":"855","volume":"49","author":"A Zimran","year":"1991","unstructured":"Zimran A, Gelbart T, Westwood B, Grabowski GA, Beutler E. High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews. Am J Hum Genet. 1991;49:855\u20139.","journal-title":"Am J Hum Genet"},{"issue":"Suppl 1","key":"174_CR5","doi-asserted-by":"crossref","first-page":"A2","DOI":"10.1259\/bjr.75.suppl_1.750002","volume":"75","author":"RJ Wenstrup","year":"2002","unstructured":"Wenstrup RJ, Roca-Espiau M, Weinreb NJ, Bembi B. Skeletal aspects of Gaucher disease: a review. Br J Radiol. 2002;75(Suppl 1):A2\u201312.","journal-title":"Br J Radiol"},{"key":"174_CR6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/archpedi.160.6.603","volume":"160","author":"P Kaplan","year":"2006","unstructured":"Kaplan P, Andersson HC, Kacena KA, Yee JD. The clinical and demographic characteristics of non neuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med. 2006;160:603\u20138.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"174_CR7","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1185\/030079906X104623","volume":"22","author":"S Vom Dahl","year":"2006","unstructured":"Vom Dahl S, Poll L, Di Rocco M, et al. Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients. Curr Med Res Opin. 2006;22:1045\u201364.","journal-title":"Curr Med Res Opin."},{"key":"174_CR8","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bcmd.2010.10.011","volume":"46","author":"PK Mistry","year":"2011","unstructured":"Mistry PK, Weinreb NJ, Kaplan P, Cole JA, Gwosdow AR, Hangartner T. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults. Blood Cells Mol Dis. 2011;46:66\u201372.","journal-title":"Blood Cells Mol Dis"},{"issue":"Suppl 5","key":"174_CR9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","volume":"41","author":"GM Pastores","year":"2004","unstructured":"Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol. 2004;41(Suppl 5):4\u201314.","journal-title":"Semin Hematol"},{"key":"174_CR10","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","volume":"113","author":"NJ Weinreb","year":"2002","unstructured":"Weinreb NJ, Charrow J, Andersson HC, et al. Effectiveness of enzyme replacement therapy in 1,028 patients with type 1 Gaucher disease after 2\u20135\u00a0years of treatment: a report from the Gaucher Registry. Am J Med. 2002;113:112\u20139.","journal-title":"Am J Med"},{"key":"174_CR11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1359\/jbmr.061004","volume":"22","author":"RJ Wenstrup","year":"2007","unstructured":"Wenstrup RJ, Kacena KA, Kaplan P, et al. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res. 2007;22:119\u201326.","journal-title":"J Bone Miner Res"},{"key":"174_CR12","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/MD.0b013e3182057be4","volume":"90","author":"PB Deegan","year":"2011","unstructured":"Deegan PB, Pavlova E, Tindall J, et al. Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy. Medicine (Baltimore). 2011;90:52\u201360.","journal-title":"Medicine (Baltimore)."},{"key":"174_CR13","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1542\/peds.2007-2144","volume":"122","author":"H Andersson","year":"2008","unstructured":"Andersson H, Kaplan P, Kacena K, et al. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics. 2008;122:1182\u201390.","journal-title":"Pediatrics"},{"key":"174_CR14","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2009.07872.x","volume":"147","author":"PK Mistry","year":"2009","unstructured":"Mistry PK, Deegan P, Vellodi A, et al. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis. Br J Haematol. 2009;147:561\u201370.","journal-title":"Br J Haematol"},{"key":"174_CR15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1023\/A:1008814105603","volume":"7","author":"AM Damiano","year":"1998","unstructured":"Damiano AM, Pastores GM, Ware JE Jr. The health-related quality of life of adults with Gaucher\u2019s disease receiving enzyme replacement therapy: results from a retrospective study. Qual Life Res. 1998;7:373\u201386.","journal-title":"Qual Life Res"},{"key":"174_CR16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11136-004-0794-y","volume":"14","author":"P Giraldo","year":"2005","unstructured":"Giraldo P, Solano V, P\u00e9rez-Calvo JI, Giralt M, Rubio-F\u00e9lix D, Spanish Group on Gaucher disease. Quality of life related to type 1 Gaucher disease: Spanish experience. Qual Life Res. 2005;14:453\u201362.","journal-title":"Qual Life Res"},{"issue":"Suppl 5","key":"174_CR17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminhematol.2004.07.010","volume":"41","author":"NJ Weinreb","year":"2004","unstructured":"Weinreb NJ, Aggio MC, Andersson HC, et al. Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol. 2004;41(Suppl 5):15\u201322.","journal-title":"Semin Hematol"},{"key":"174_CR18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00256-007-0425-0","volume":"37","author":"M Maas","year":"2008","unstructured":"Maas M, Hangartner T, Mariani G, et al. Recommendations for the assessment and monitoring of skeletal manifestations in children with Gaucher disease. Skeletal Radiol. 2008;37:185\u20138.","journal-title":"Skeletal Radiol"},{"key":"174_CR19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00467-009-1249-z","volume":"25","author":"ML Bianchi","year":"2010","unstructured":"Bianchi ML, Baim S, Bishop NJ, et al. Official positions of the International Society for Clinical Densitometry (ISCD) on DXA evaluation in children and adolescents. Pediatr Nephrol. 2010;25:37\u201347.","journal-title":"Pediatr Nephrol"},{"key":"174_CR20","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jocd.2013.08.004","volume":"16","author":"JT Schousboe","year":"2013","unstructured":"Schousboe JT, Shepherd JA, Bilezikian JP, Baim S. Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J Clin Densitom. 2013;16:455\u201366.","journal-title":"J Clin Densitom"},{"key":"174_CR21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jocd.2007.12.005","volume":"11","author":"CM Gordon","year":"2008","unstructured":"Gordon CM, Bachrach LK, Carpenter TO, et al. Dual energy X-ray absorptiometry interpretation and reporting in children and adolescents: the 2007 ISCD Pediatric Official Positions. J Clin Densitom. 2008;11:43\u201358.","journal-title":"J Clin Densitom."},{"key":"174_CR22","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1359\/JBMR.050304","volume":"20","author":"O Johnell","year":"2005","unstructured":"Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005;20:1185\u201394.","journal-title":"J Bone Miner Res"},{"key":"174_CR23","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00431-012-1771-z","volume":"172","author":"P Kaplan","year":"2013","unstructured":"Kaplan P, Baris H, De Meirleir L, et al. Revised recommendations for the management of Gaucher disease in children. Eur J Pediatr. 2013;172:447\u201358.","journal-title":"Eur J Pediatr"},{"key":"174_CR24","doi-asserted-by":"crossref","first-page":"802","DOI":"10.2106\/00004623-198668060-00002","volume":"68","author":"DI Rosenthal","year":"1986","unstructured":"Rosenthal DI, Scott JA, Barranger J, et al. Evaluation of Gaucher disease using magnetic resonance imaging. J Bone Joint Surg Am. 1986;68:802\u20138.","journal-title":"J Bone Joint Surg Am"},{"key":"174_CR25","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s002560100375","volume":"30","author":"LW Poll","year":"2001","unstructured":"Poll LW, Koch JA, vom Dahl S. Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results. Skeletal Radiol. 2001;30:496\u2013503.","journal-title":"Skeletal Radiol"},{"key":"174_CR26","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s002560000276","volume":"29","author":"MR Terk","year":"2000","unstructured":"Terk MR, Dardashti S, Liebman HA. Bone marrow response in treated patients with Gaucher disease: evaluation by T1-weighted magnetic resonance images and correlation with reduction in liver and spleen volume. Skeletal Radiol. 2000;29:563\u201371.","journal-title":"Skeletal Radiol"},{"key":"174_CR27","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/00004728-200209000-00031","volume":"26","author":"EJ Vlieger","year":"2002","unstructured":"Vlieger EJ, Maas M, Akkerman EM, Hollak CE, Den Heeten GJ. Vertebra disc ratio as a parameter for bone marrow involvement and its application in Gaucher disease. J Comput Assist Tomogr. 2002;26:843\u20138.","journal-title":"J Comput Assist Tomogr"},{"key":"174_CR28","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1148\/radiol.2292020296","volume":"229","author":"M Maas","year":"2003","unstructured":"Maas M, van Kuijk C, Stoker J, et al. Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging\u2014initial experience. Radiology. 2003;229:554\u201361.","journal-title":"Radiology"},{"key":"174_CR29","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejrad.2006.11.024","volume":"62","author":"M Roca","year":"2007","unstructured":"Roca M, Mota J, Alfonso P, Pocov\u00ed M, Giraldo P. S-MRI score: a simple method for assessing bone marrow involvement in Gaucher disease. Eur J Radiol. 2007;62:132\u20137.","journal-title":"Eur J Radiol"},{"key":"174_CR30","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2214\/ajr.179.4.1790961","volume":"179","author":"M Maas","year":"2002","unstructured":"Maas M, Hollak CE, Akkerman EM, Aerts JM, Stoker J, Den Heeten GJ. Quantification of skeletal involvement in adults with type I Gaucher\u2019s disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter. AJR Am J Roentgenol. 2002;179:961\u20135.","journal-title":"AJR Am J Roentgenol"},{"key":"174_CR31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bcmd.2010.10.005","volume":"46","author":"LW Poll","year":"2011","unstructured":"Poll LW, Cox ML, Godehardt E, Steinhof V, vom Dahl S. Whole body MRI in type I Gaucher patients: evaluation of skeletal involvement. Blood Cells Mol Dis. 2011;46:53\u20139.","journal-title":"Blood Cells Mol Dis"},{"key":"174_CR32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1302\/0301-620X.67B1.3155745","volume":"67","author":"RP Ficat","year":"1985","unstructured":"Ficat RP. Idiopathic bone necrosis of the femoral head. Early diagnosis and treatment. J Bone Joint Surg Br. 1985;67:3\u20139.","journal-title":"J Bone Joint Surg Br"},{"key":"174_CR33","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/blood.V96.5.1969","volume":"96","author":"MT Moran","year":"2000","unstructured":"Moran MT, Schofield JP, Hayman AR, Shi GP, Young E, Cox TM. Pathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K. Blood. 2000;96:1969\u201378.","journal-title":"Blood"},{"key":"174_CR34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1006\/bcmd.2001.0479","volume":"28","author":"C Drugan","year":"2002","unstructured":"Drugan C, Jebeleanu G, Grigorescu-Sido P, Caillaud C, Craciun AM. Biochemical markers of bone turnover as tools in the evaluation of skeletal involvement in patients with type 1 Gaucher disease. Blood Cells Mol Dis. 2002;28:13\u201320.","journal-title":"Blood Cells Mol Dis"},{"key":"174_CR35","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10545-005-0032-y","volume":"28","author":"G Ciana","year":"2005","unstructured":"Ciana G, Addobbati R, Tamaro G, et al. Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy. J Inherit Metab Dis. 2005;28:723\u201332.","journal-title":"J Inherit Metab Dis"},{"key":"174_CR36","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bcmd.2005.05.005","volume":"35","author":"PB Deegan","year":"2005","unstructured":"Deegan PB, Moran MT, McFarlane I, et al. Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cells Mol Dis. 2005;35:259\u201367.","journal-title":"Blood Cells Mol Dis"},{"key":"174_CR37","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10545-005-0585-9","volume":"28","author":"A Vellodi","year":"2005","unstructured":"Vellodi A, Foo Y, Cole TJ. Evaluation of three biochemical markers in the monitoring of Gaucher disease. J Inherit Metab Dis. 2005;28:585\u201392.","journal-title":"J Inherit Metab Dis"},{"key":"174_CR38","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00223-008-9143-4","volume":"83","author":"P Mikosch","year":"2008","unstructured":"Mikosch P, Reed M, Baker R, et al. Changes of bone metabolism in seven patients with Gaucher disease treated consecutively with imiglucerase and miglustat. Calcif Tissue Int. 2008;83:43\u201354.","journal-title":"Calcif Tissue Int"},{"key":"174_CR39","doi-asserted-by":"crossref","first-page":"R156","DOI":"10.1186\/ar3111","volume":"12","author":"J Stirnemann","year":"2010","unstructured":"Stirnemann J, Belmatoug N, Vincent C, Fain O, Fantin B, Mentr\u00e9 F. Bone events and evolution of biologic markers in Gaucher disease before and during treatment. Arthritis Res Ther. 2010;12:R156.","journal-title":"Arthritis Res Ther."},{"key":"174_CR40","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1210\/jc.2011-0162","volume":"96","author":"L Dussen van","year":"2011","unstructured":"van Dussen L, Lips P, Everts VE, et al. Markers of bone turnover in Gaucher disease: modeling the evolution of bone disease. J Clin Endocrinol Metab. 2011;96:2194\u2013205.","journal-title":"J Clin Endocrinol Metab"},{"key":"174_CR41","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/00005792-198509000-00003","volume":"64","author":"DW Stowens","year":"1985","unstructured":"Stowens DW, Teitelbaum SL, Kahn AJ, Barranger JA. Skeletal complications of Gaucher disease. Medicine (Baltimore). 1985;64:310\u201322.","journal-title":"Medicine (Baltimore)."},{"key":"174_CR42","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.4081\/hr.2012.e21","volume":"4","author":"G Giuffrida","year":"2012","unstructured":"Giuffrida G, Cingari MR, Parrinello N, et al. Bone turnover markers in patients with type 1 Gaucher disease. Hematol Rep. 2012;4:e21.","journal-title":"Hematol Rep."},{"key":"174_CR43","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","volume":"122","author":"GA Grabowski","year":"1995","unstructured":"Grabowski GA, Barton NW, Pastores G, et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med. 1995;122:33\u20139.","journal-title":"Ann Intern Med"},{"key":"174_CR44","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-02-268649","volume":"115","author":"A Zimran","year":"2010","unstructured":"Zimran A, Altarescu G, Philips M, et al. Phase 1\/2 and extension study of velaglucerasealfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood. 2010;115:4651\u20136.","journal-title":"Blood"},{"key":"174_CR45","doi-asserted-by":"crossref","first-page":"e4792","DOI":"10.1371\/journal.pone.0004792","volume":"4","author":"D Aviezer","year":"2009","unstructured":"Aviezer D, Brill-Almon E, Shaaltiel Y, et al. A plant-derived recombinant human glucocerebrosidase enzyme\u2014a preclinical and phase I investigation. PLoS One. 2009;4:e4792.","journal-title":"PLoS One"},{"key":"174_CR46","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2006.09.003","volume":"90","author":"K Starzyk","year":"2007","unstructured":"Starzyk K, Richards S, Yee J, Smith SE, Kingma W. The long-term international safety experience of imiglucerase therapy for Gaucher disease. Mol Genet Metab. 2007;90:157\u201363.","journal-title":"Mol Genet Metab"},{"key":"174_CR47","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood-2005-12-5072","volume":"108","author":"M Fost de","year":"2006","unstructured":"de Fost M, Hollak CE, Groener JE, et al. Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis. Blood. 2006;108:830\u20135.","journal-title":"Blood"},{"key":"174_CR48","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10545-010-9071-0","volume":"33","author":"S Piran","year":"2010","unstructured":"Piran S, Amato D. Gaucher disease: a systematic review and meta-analysis of bone complications and their response to treatment. J Inherit Metab Dis. 2010;33:271\u20139.","journal-title":"J Inherit Metab Dis"},{"key":"174_CR49","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.2214\/AJR.06.1410","volume":"188","author":"PL Robertson","year":"2007","unstructured":"Robertson PL, Maas M, Goldblatt J. Semi-quantitative assessment of skeletal response to enzyme replacement therapy for Gaucher\u2019s disease using the bone marrow burden score. AJR Am J Roentgenol. 2007;188:1521\u20138.","journal-title":"AJR Am J Roentgenol"},{"key":"174_CR50","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/ajh.21280","volume":"83","author":"N Weinreb","year":"2008","unstructured":"Weinreb N, Taylor J, Cox T, Yee J, vom Dahl S. A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase. Am J Hematol. 2008;83:890\u20135.","journal-title":"Am J Hematol"},{"key":"174_CR51","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/01.GIM.0000153660.88672.3C","volume":"7","author":"HC Andersson","year":"2005","unstructured":"Andersson HC, Charrow J, Kaplan P, et al. Individualization of long-term enzyme replacement therapy for Gaucher disease. Genet Med. 2005;7:105\u201310.","journal-title":"Genet Med."},{"key":"174_CR52","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1023\/A:1025902113005","volume":"26","author":"TM Cox","year":"2003","unstructured":"Cox TM, Aerts JM, Andria G, et al. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis. 2003;26:513\u201326.","journal-title":"J Inherit Metab Dis"},{"key":"174_CR53","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/pds.1779","volume":"18","author":"CE Hollak","year":"2009","unstructured":"Hollak CE, Hughes D, van Schaik IN, Schwierin B, Bembi B. Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme. Pharmacoepidemiol Drug Saf. 2009;18:770\u20137.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"174_CR54","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1182\/blood-2010-06-293902","volume":"116","author":"E Lukina","year":"2010","unstructured":"Lukina E, Watman N, Arreguin EA, et al. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood. 2010;116:4095\u20138.","journal-title":"Blood"},{"key":"174_CR55","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2010-03-273151","volume":"116","author":"E Lukina","year":"2010","unstructured":"Lukina E, Watman N, Arreguin EA, et al. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood. 2010;116:893\u20139.","journal-title":"Blood"},{"key":"174_CR56","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1182\/blood-2003-11-3854","volume":"104","author":"RJ Wenstrup","year":"2004","unstructured":"Wenstrup RJ, Bailey L, Grabowski GA, et al. Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood. 2004;104:1253\u20137.","journal-title":"Blood"},{"key":"174_CR57","first-page":"260","volume":"61","author":"S Adami","year":"2009","unstructured":"Adami S, Bertoldo F, Brandi ML, et al. Guidelines for the diagnosis, prevention and treatment of osteoporosis. Reumatismo. 2009;61:260\u201384.","journal-title":"Reumatismo."},{"key":"174_CR58","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s10545-008-0873-2","volume":"31","author":"J Cox-Brinkman","year":"2008","unstructured":"Cox-Brinkman J, van Breemen MJ, van Maldegem BT, et al. Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III. J Inherit Metab Dis. 2008;31:745\u201352.","journal-title":"J Inherit Metab Dis"},{"key":"174_CR59","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1182\/blood-2007-02-075960","volume":"110","author":"D Elstein","year":"2007","unstructured":"Elstein D, Dweck A, Attias D, et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood. 2007;110:2296\u2013301.","journal-title":"Blood"},{"key":"174_CR60","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00003086-198912000-00021","volume":"249","author":"ME Steinberg","year":"1989","unstructured":"Steinberg ME, Brighton CT, Corces A. Osteonecrosis of the femoral head; results of core depression and grafting with electrical stimulation. Clin Orthop. 1989;249:199\u2013208.","journal-title":"Clin Orthop"},{"key":"174_CR61","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10545-012-9528-4","volume":"36","author":"NJ Weinreb","year":"2013","unstructured":"Weinreb NJ, Goldblatt J, Villalobos J, et al. Long-term clinical outcomes in type 1 Gaucher disease following 10\u00a0years of imiglucerase treatment. J Inherit Metab Dis. 2013;36:543\u201353.","journal-title":"J Inherit Metab Dis"},{"key":"174_CR62","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1399-0004.2008.00978.x","volume":"73","author":"KB Sims","year":"2008","unstructured":"Sims KB, Pastores GM, Weinreb NJ, et al. Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Clin Genet. 2008;73:430\u201340.","journal-title":"Clin Genet"},{"key":"174_CR63","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1399-0004.2007.00769.x","volume":"71","author":"J Charrow","year":"2007","unstructured":"Charrow J, Dulisse B, Grabowski GA, Weinreb NJ. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet. 2007;71:205\u201311.","journal-title":"Clin Genet"},{"key":"174_CR64","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bcmd.2011.04.005","volume":"47","author":"D Elstein","year":"2011","unstructured":"Elstein D, Foldes AJ, Zahrieh D, et al. Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerasealfa: 69-month experience, including dose reduction. Blood Cells Mol Dis. 2011;47:56\u201361.","journal-title":"Blood Cells Mol Dis"},{"key":"174_CR65","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bcmd.2014.02.006","volume":"53","author":"D Elstein","year":"2014","unstructured":"Elstein D, Haims AH, Zahrieh D, Cohn GM, Zimran A. Impact of velaglucerasealfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-Year follow-up. Blood Cells Mol Dis. 2014;53:56\u201360.","journal-title":"Blood Cells Mol Dis"},{"key":"174_CR66","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1399-0004.2007.00811.x","volume":"71","author":"N Weinreb","year":"2007","unstructured":"Weinreb N, Barranger J, Packman S, et al. Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease. Clin Genet. 2007;71:576\u201388.","journal-title":"Clin Genet"},{"key":"174_CR67","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/PL00008411","volume":"160","author":"H Ida","year":"2001","unstructured":"Ida H, Rennert OM, Kobayashi M, Eto Y. Effects of enzyme replacement therapy in thirteen Japanese paediatric patients with Gaucher disease. Eur J Pediatr. 2001;160:21\u20135.","journal-title":"Eur J Pediatr"}],"updated-by":[{"DOI":"10.1007\/s12325-015-0196-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2015,4,3]],"date-time":"2015-04-03T00:00:00Z","timestamp":1428019200000}}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-014-0174-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-014-0174-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-014-0174-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T13:04:14Z","timestamp":1650805454000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-014-0174-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":67,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["174"],"URL":"https:\/\/doi.org\/10.1007\/s12325-014-0174-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12]]}}}